Live from the NIH registry
Studies recruiting near Fort Wayne right now
Top 25 of 118 recruiting studies, sorted by proximity — each links to its official registry page
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1
Interventional 694 participants sought
Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AbbVie
Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis
Gingivitis, Plaque
Phase 4
Interventional 100 participants sought
Salus Research, Inc. — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Colgate Palmolive
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Metastatic Non-small Cell Lung Cancer
Phase 3
Interventional 734 participants sought
Parkview Packnett Family Cancer Institute — Fort Wayne, Indiana (3.0 mi)
· Sponsor: NovoCure GmbH
C-Brace Prospective Registry
Pareses, Lower Extremity
N/A
Observational 250 participants sought
Prevail Prosthetics & Orthotics — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Otto Bock Healthcare Products GmbH
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Neoplasm, Colorectal, Cognitive Impairment
N/A
Observational 60 participants sought
Parkview Cancer Institute — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Joseph McCollom
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Phase 3
Interventional 1,160 participants sought
Research Site — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AstraZeneca
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Phase 3
Interventional 621 participants sought
Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana (3.0 mi)
· Sponsor: BioNTech SE
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
Degenerative Disc Disease, Lumbar Disc Disease
Phase 1, Phase 2
Interventional 40 participants sought
Orthopaedics NorthEast — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Locate Bio Pty Ltd
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
Mental Health, Conflict
N/A
Interventional 1,800 participants sought
Fort Wayne Center for Children and Families — Fort Wayne, Indiana (3.0 mi)
· Sponsor: University of Notre Dame
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
End Stage Kidney Disease
Phase 2, Phase 3
Interventional 3,110 participants sought
NANI Research — Fort Wayne, Indiana (3.0 mi)
· Sponsor: CSL Behring
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic
Phase 3
Interventional 735 participants sought
Fort Wayne Medical Oncology and Hematology ( Site 5444) — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Endometrial Cancer, Malignant Solid Tumour
Phase 3
Interventional 800 participants sought
Research Site — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AstraZeneca
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Radiation Oncology Associates PC — Fort Wayne, Indiana (3.0 mi)
· Sponsor: National Cancer Institute (NCI)
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Melanoma
Phase 3
Interventional 560 participants sought
Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Regeneron Pharmaceuticals
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Idiopathic Hypersomnia
Phase 3
Interventional 248 participants sought
Fort Wayne Neurological Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Harmony Biosciences Management, Inc.
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
Stomatitis
Phase 4
Interventional 100 participants sought
Research Site — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AstraZeneca
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
Peripheral Vascular Diseases
N/A
Observational 5,000 participants sought
St. Joseph Hospital/Dupont Hospital — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Boston Scientific Corporation
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Epithelial Ovarian Cancer
Phase 3
Interventional 1,100 participants sought
Research Site — Fort Wayne, Indiana (3.0 mi)
· Sponsor: AstraZeneca
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Chronic Kidney Diseases, End Stage Renal Disease
N/A
Interventional 600 participants sought
Lutheran Medical Group — Fort Wayne, Indiana (3.0 mi)
· Sponsor: VenoStent
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Phase 3
Interventional 49 participants sought
Study Site 101 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Grifols Biologicals, LLC
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Phase 3
Interventional 336 participants sought
Parkview Regional Medical Center — Fort Wayne, Indiana (3.0 mi)
· Sponsor: National Cancer Institute (NCI)
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (CRC)
Phase 3
Interventional 600 participants sought
Clinical Study Site — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Summit Therapeutics
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Non Small Cell Lung Cancer
Phase 3
Interventional 630 participants sought
Fort Wayne Medical Oncology - 1133 — Fort Wayne, Indiana (3.0 mi)
· Sponsor: OncoC4, Inc.
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 1,200 participants sought
Parkview Research Center at Parkview Regional Medical Center ( Site 0002) — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Merck Sharp & Dohme LLC
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
Chemotherapy Induced Peripheral Neuropathy (CIPN)
N/A
Interventional 142 participants sought
Parkview Cancer Institute — Fort Wayne, Indiana (3.0 mi)
· Sponsor: Luminate Medical, Inc.